[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, Labidi SI, Treilleux I, Rivoire M, Ray-Coquard I: Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer; 2010 Apr;97(4):E23-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
  • OBJECTIVE: To assess the feasibility and efficacy of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) without adjuvant chemotherapy for relapsed or persistent advanced ovarian cancer.
  • METHODS: This observational study included stage IIIC ovarian cancer patients due to undergo CRS (interval debulking or recurrent surgery) followed by HIPEC with oxaliplatin (460 mg/m2) for 30 min.
  • Median peritoneal cancer index at surgery was 6 (range: 1-18).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced / methods. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202920.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


2. Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS: The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol; 2010 Mar;116(3):351-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
  • OBJECTIVE: Our objective was to analyze the effect of surgical outcome on progression-free survival (PFS) and overall survival (OS) of patients with advanced ovarian carcinoma stratified by the initial presence and volume of upper abdominal disease cephalad to the greater omentum (UAD) found at the time of exploration.
  • METHODS: We evaluated all patients with FIGO stage IIIC ovarian carcinoma who underwent primary cytoreduction followed by platinum-based chemotherapy at our institution between January 1989 and December 2006.
  • The findings support the management strategy of maximizing surgical efforts with increasing tumor burden in patients with stage IIIC ovarian cancer.
  • [MeSH-major] Omentum / pathology. Omentum / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022092.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds
  • [Other-IDs] NLM/ NIHMS774763; NLM/ PMC4843127
  •  go-up   go-down


3. Samaritani R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer; 2007;7:65
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
  • BACKGROUND: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.
  • CASE PRESENTATION: We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Palliative Care. Salvage Therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):12-5 [11863092.001]
  • [Cites] Lancet Oncol. 2001 Dec;2(12):733-40 [11902515.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):179-86 [12063566.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Nov;2(11):562-77 [16270097.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Minerva Ginecol. 2004 Feb;56(1):81-9 [14973412.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):939-52 [15557593.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):916-23 [15907981.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6938-43 [12460910.001]
  • (PMID = 17433113.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Vitamins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1863429
  •  go-up   go-down


Advertisement
4. Kim H, Watkinson J, Varadan V, Anastassiou D: Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics; 2010;3:51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1.
  • BACKGROUND: Despite extensive research, the details of the biological mechanisms by which cancer cells acquire motility and invasiveness are largely unknown.
  • METHODS: We analyze data from multiple cancers using a novel computational method identifying sets of genes whose coordinated overexpression indicates the presence of a particular phenotype, in this case high-stage cancer.
  • RESULTS: We conclude that there is one shared "core" metastasis-associated gene expression signature corresponding to a specific variant of stromal desmoplastic reaction, present in a large subset of samples that have exceeded a threshold of invasive transition specific to each cancer, indicating that the corresponding biological mechanism is triggered at that point.
  • For example this threshold is reached at stage IIIc in ovarian cancer and at stage II in colorectal cancer.
  • Therefore, its presence indicates that the corresponding stage has been reached.
  • The prominent presence in the signature of INHBA in all cancers strongly suggests a biological mechanism centered on activin A induced TGF-β signaling, because activin A is a member of the TGF-β superfamily consisting of an INHBA homodimer.
  • Furthermore, we establish that the signature is predictive of neoadjuvant therapy response in at least one breast cancer data set.
  • CONCLUSIONS: Therefore, these results can be used for developing high specificity biomarkers sensing cancer invasion and predicting response to neoadjuvant therapy, as well as potential multi-cancer metastasis inhibiting therapeutics targeting the corresponding biological mechanism.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 23;335(2):631-6 [16098915.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):981-8 [17016581.001]
  • [Cites] Mol Syst Biol. 2007;3:83 [17299419.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Life Sci. 2000 Mar;66(17):1603-13 [11261590.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):851-61 [17486574.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4284-94 [17297478.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):624-6 [18245519.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):660-7 [18245525.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38 [18628784.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Nat Med. 2009 Jan;15(1):68-74 [19122658.001]
  • [Cites] Hepatogastroenterology. 2008 Nov-Dec;55(88):2016-27 [19260470.001]
  • [Cites] Ann N Y Acad Sci. 2009 Mar;1158:302-13 [19348651.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):958-68 [19914252.001]
  • [Cites] Cell. 2010 Apr 2;141(1):52-67 [20371345.001]
  • [Cites] Am J Pathol. 2010 Sep;177(3):1053-64 [20651229.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):295-302 [15023835.001]
  • (PMID = 21047417.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type XI; 0 / MicroRNAs; 0 / Thrombospondins; 0 / inhibin beta A subunit; 0 / thrombospondin 2; 93443-12-0 / Inhibin-beta Subunits
  • [Other-IDs] NLM/ PMC2988703
  •  go-up   go-down


5. Muramatsu T, Yamashita E, Takahashi K, Sugiyama T, Tsukada H, Kondo A, Hirasawa T, Murakami M, Yasuda S, Mikami M: Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125. Tokai J Exp Clin Med; 2007 Mar;32(1):23-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125.
  • We report the case of a 41-year-old patient with epithelial ovarian cancer of stage IIIc.
  • This allowed commencement of chemotherapy at an early recurrent stage and subsequently the level of CA125 showed a significant decrease.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Lymphatic Metastasis / diagnosis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / therapy. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Ovarian Neoplasms / prevention & control. Ovarian Neoplasms / therapy. Recurrence

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319052.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; Ovarian epithelial cancer
  •  go-up   go-down


6. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS: Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol; 2009 Nov;115(2):209-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
  • OBJECTIVE: To analyze whether serum CA-125 response to cytoreductive surgery before initiation of postoperative chemotherapy is associated with progression-free survival (PFS) in patients with stage IIIC ovarian carcinoma.
  • CONCLUSION: Perioperative serum CA-125 changes are strongly associated with the risk of relapse in patients with optimally resected stage IIIC disease.
  • [MeSH-major] CA-125 Antigen / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 May 1;97(9):2187-95 [12712470.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):307-12 [3164697.001]
  • [Cites] Gynakol Rundsch. 1990;30 Suppl 1:210-1 [2079273.001]
  • [Cites] Eur J Cancer. 1993;29A(7):966-71 [8499150.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):42-7 [7789889.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1545-51 [8622070.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):361-4 [8805927.001]
  • [Cites] N Engl J Med. 1996 Nov 7;335(19):1413-6 [8875917.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):234-7 [8910633.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):47-50 [15598937.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1454-8 [16549840.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1234-8 [16766592.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):195-8 [16595148.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):176-80 [16996584.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • [Cites] Cancer. 2009 Mar 1;115(5):1028-35 [19156927.001]
  • [Cites] JAMA. 2000 May 3;283(17):2260-5 [10807385.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5 [10995813.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4054-7 [11600607.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):487-8 [15026475.001]
  • (PMID = 19664812.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Organoplatinum Compounds
  • [Other-IDs] NLM/ NIHMS523348; NLM/ PMC3870341
  •  go-up   go-down


7. Ang D, Ng KY, Tan HK, Chung AY, Yew BS, Lee VK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singapore; 2007 Jun;36(6):427-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report.
  • INTRODUCTION: Ovarian carcinoma usually presents at an advanced stage with diffuse intraabdominal manifestations.
  • A computed tomography (CT) scan showed an enlarged left ovarian lesion (9.0 x 6.4 cm).
  • Histology confirmed left ovarian adenocarcinoma, consistent with the earlier histology of the right inguinal lymph node.
  • Postoperatively, the patient received adjuvant chemotherapy for treatment of FIGO Stage IIIc ovarian carcinoma and is clinically disease free 13 months after surgery.
  • CONCLUSIONS: Ovarian cancer presenting with inguinal lymph node metastases is uncommon.
  • Ovarian cancer which manifests solely as a contralateral inguinal lymph node metastasis has not been previously reported.
  • This case illustrates a rare presentation of ovarian carcinoma, and underscores the need to consider ovarian carcinoma in the differential diagnosis of women with inguinal lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597969.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


8. Zhang J, Grifo JA, Del Priore G: Gestational carrier pregnancy with oocytes obtained during surgery for stage IIIc ovarian cancer after controlled ovarian stimulation. Fertil Steril; 2005 May;83(5):1547-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational carrier pregnancy with oocytes obtained during surgery for stage IIIc ovarian cancer after controlled ovarian stimulation.
  • OBJECTIVE: To report a case of gestational carrier pregnancy with oocytes from a stage IIIc ovarian cancer patient.
  • PATIENT: A 38-year-old woman with stage IIIc ovarian cancer.
  • INTERVENTION(S): Controlled ovarian stimulation, cancer surgery, and IVF-ET to a gestational carrier.
  • CONCLUSION(S): Cryopreservation of embryos derived from IVF of oocytes obtained from ovarian cancer patients should be an option for their future fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Oocytes. Ovarian Neoplasms / surgery. Ovulation Induction / methods. Surrogate Mothers

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15866597.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Terauchi F, Kobayashi Y, Nagashima T, Moritake T, Nishi H, Fujito A, Isaka K: Pilot study on transdiaphragmatic thoracoscopic-assisted pleural biopsy and intrathoracic washing cytology for Stage IIIc ovarian cancer with diaphragmatic metastases. Int J Gynecol Cancer; 2009 Feb;19(2):300-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study on transdiaphragmatic thoracoscopic-assisted pleural biopsy and intrathoracic washing cytology for Stage IIIc ovarian cancer with diaphragmatic metastases.
  • PURPOSE: The significance of investigations of thoracic cavities as well as pleural biopsy and intrathoracic washing cytology through transdiaphragmatic thoracoscopy for stage IIIc ovarian cancer with diaphragmatic metastases was assessed as a prospective pilot study.
  • SUBJECTS AND METHODS: Eligibility criteria were established to include patients with stage IIIc ovarian cancer in whom pleural effusions were not detected preoperationally, but prominent diaphragmatic metastases were observed when the abdomen was opened and those who submitted consent.
  • Hence, a total of 7 subjects (70.0%) were up-staged to the level of stage IV.
  • CONCLUSIONS: It was suggested that stage IIIc ovarian cancer with prominent diaphragmatic metastasis may advance to the level of stage IV from a clinical point of view even if carcinomatous pleural effusions are not detected pre-operationally.
  • Therefore, it is thought that this operational method is useful in the management of progressive ovarian cancer.
  • [MeSH-major] Muscle Neoplasms / pathology. Ovarian Neoplasms / pathology. Pleura / pathology. Thoracic Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396013.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Oksefjell H, Sandstad B, Tropé C: Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001. Eur J Gynaecol Oncol; 2007;28(4):256-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001.
  • BACKGROUND: The aim of this study was to evaluate the treatment of FIGO Stage IIIC patients who were primarily treated completely or partially at the Norwegian Radium Hospital (NRH) during a 15-year period in order to discover possibilities for improvement of prognosis of advanced ovarian cancer.
  • MATERIALS AND METHOD: A retrospective study based on record information from all patients with epithelial ovarian cancer Stage IIIC treated at NRH from 1985-2000, in total 776 patients.
  • We believe that further centralisation of primary surgery for advanced ovarian cancer can contribute to a better prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Middle Aged. Norway. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713088.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Jakobsen DH, Høgdall C, Kehlet H: [Perioperative care of patients with stage IIIC ovarian cancer]. Ugeskr Laeger; 2010 Sep 27;172(39):2688-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perioperative care of patients with stage IIIC ovarian cancer].
  • [Transliterated title] Perioperativ behandling af ovariecancer i stadium IIIC.
  • INTRODUCTION: Besides intraoperative efforts, the perioperative care is essential to improve the postoperative outcome following ovarian cancer surgery.
  • The purpose of this study was to assess and discuss perioperative care principles in patients undergoing ovarian cancer surgery with stage IIIC at the six centres in Denmark performing this surgical procedure.
  • CONCLUSION: Mobilization, nutrition, nausea and pain are severe problems for patients undergoing ovarian cancer surgery.
  • [MeSH-major] Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20920397.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


12. Oksefjell H, Sandstad B, Trope C: Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival. Eur J Gynaecol Oncol; 2006;27(3):209-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival.
  • BACKGROUND: Maximum cytoreduction at primary surgery has been found to be one of the strongest prognostic factors for survival of ovarian cancer.
  • The aim of the study was to investigate the influence of hospital level (primary vs secondary care centre), number and timing of surgery and chemotherapy on how radical the surgery was at primary treatment of epithelial ovarian cancer Stage IIIC.
  • MATERIAL AND METHODS: A retrospective study based on record information from all patients with epithelial ovarian cancer Stage IIIC treated at the Norwegian Radium Hospital (NRH) 1985-2000, in total 776, subdivided into four groups:.
  • Lymph node biopsies at re-operation in early stages and upgrading of stage where necessary were registered.
  • Most lymph node biopsies were performed during the last period and 28% were upgraded from Stage I and II to IIIC.
  • [MeSH-major] Carcinoma / surgery. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800244.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Berek JS: Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer; 2009 Dec;19 Suppl 2:S18-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node-positive stage IIIC ovarian cancer: a separate entity?
  • INTRODUCTION: Ovarian cancer spreads via the retroperitoneal lymphatics, and these lymph nodes frequently contain metastasis.
  • A subset of patients whose disease was classified as stage IIIC has retroperitoneal lymph node metastases in the pelvic and/or para-aortic lymph nodes without intraperitoneal carcinomatosis and was upstaged from stage I to IIIB diseases based on these findings.
  • Patients undergoing cytoreductive surgery for advanced-stage ovarian cancer undergo concomitant retroperitoneal lymphadenectomy in an effort to improve their survival.
  • METHODS: Stratification of patients with stage IIIC ovarian cancer by lymph node status and presence and extent of metastatic disease in the peritoneal cavity has been performed.
  • RESULTS: The overall survival of patients with stage IIIC ovarian cancer based on retroperitoneal lymph node metastasis without peritoneal carcinomatosis is 58% to 84% compared with 18% to 36% for those with macroscopic peritoneal carcinomatosis.
  • Although the performance of a pelvic and para-aortic lymphadenectomy in patients with stage IIIC to IV diseases has been reported to prolong survival, an international randomized study did not confirm this finding.
  • CONCLUSIONS: These data support the stratification of patients with stage IIIC ovarian cancer based on the finding of metastasis to the retroperitoneal lymph nodes without peritoneal carcinomatosis versus those who have peritoneal carcinomatosis.
  • The International Federation of Gynecology and Obstetrics Committee should consider modifying the ovarian cancer staging system by further stratifying stage III disease.
  • [MeSH-major] Carcinoma / classification. Carcinoma / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955908.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


14. Terauchi F, Nishi H, Moritake T, Kobayashi Y, Nagashima T, Onodera T, Fujito A, Nakayama D, Isaka K: Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer. J Obstet Gynaecol Res; 2009 Apr;35(2):315-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer.
  • OBJECTIVES: The aim of this study was to assess the prognostic factor of radical surgery in patients with stage IIIc ovarian cancer.
  • CONCLUSIONS: OPCS should be performed with maximum effort to improve the prognosis of stage IIIc ovarian cancer.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / surgery. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708178.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Kawashima T, Murakami H, Kanamori T, Nakamura Y: [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Gan To Kagaku Ryoho; 2007 Mar;34(3):461-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
  • An exploratory laparotomy was performed and stage IIIc ovarian cancer was diagnosed.
  • These results suggest that CPT-11+CDDP may be effective against recurrent ovarian cancer, which is difficult to treat due to its resistance to platinum drugs and taxane drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Drug Resistance, Neoplasm. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353644.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / CA-125 Antigen; 0 / Taxoids; 1605-68-1 / taxane; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


16. Hasegawa T, Nakashima A, Ishimaru M, Shima T, Hidaka T, Saito S: Carcinomatous meningitis associated with ovarian cancer complicated by SIADH. Gan To Kagaku Ryoho; 2010 Apr;37(4):739-42
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous meningitis associated with ovarian cancer complicated by SIADH.
  • We experienced a case of carcinomatous meningitis originating from stage IIIc ovarian cancer complicated by syndrome of inappropriate antidiuretic hormone secretion (SIADH).
  • A 51-year-old woman had been treated with multiple chemotherapy regimens after an initial operation for ovarian cancer.
  • [MeSH-major] Inappropriate ADH Syndrome / complications. Meningeal Carcinomatosis / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414039.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Watanabe A, Shimada M, Kigawa J, Iba T, Oishi T, Kanamori Y, Terakawa N: The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer. Int J Clin Oncol; 2005 Feb;10(1):69-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
  • We report on a 45-year-old patient with stage IIIc ovarian cancer, multiple brain metastases, and meningitis carcinomatosa.
  • Chemotherapy can help to prolong life for some patients with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Meningitis / drug therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology


18. Yamakawa H, Ariga H, Enomoto A, Netsu S, Suzuki Y, Konno R: Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy. Int J Clin Oncol; 2009 Oct;14(5):447-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy.
  • Meningeal dissemination is rare in the clinical course of ovarian carcinoma, and its prognosis is poor.
  • We report a 58-year-old woman with stage IIIc ovarian cancer who had received nine courses of adjuvant chemotherapy after surgery.
  • Meningeal dissemination of the ovarian cancer was diagnosed, as adenocarcinoma cells were found by cerebrospinal fluid (CSF) cytology.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Meningeal Carcinomatosis / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):196-204 [15102345.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):201-8 [16941075.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] Gynecol Oncol. 1984 May;18(1):119-24 [6714801.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):52-5; discussion 55 [15639526.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):157-62 [11706787.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 1992 May;13(1):81-9 [1613540.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5 [10917346.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 19856055.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3X7931PO74 / hydrocortisone acetate; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Sengupta S, Michener CM, Escobar P, Belinson J, Ganapathi R: Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol; 2008 May;109(2):226-33
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
  • OBJECTIVES: To identify proteins unique to metastatic ovarian cancer and test their potential involvement in cell adhesion.
  • METHODS: We purified plasma membrane from paired metastatic and primary tumor tissues from patients with stage IIIC ovarian cancer.
  • The role of one of the identified proteins, ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1) in cell adhesion was determined in the presence of LPA using both over-expression and down regulation approaches.
  • OCIAD1 over-expression in HEY ovarian cancer cells increased LPA-induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin 10/11.
  • CONCLUSIONS: This is the first report that OCIAD1 is over-expressed in metastatic ovarian cancer tissues.
  • The effect of OCIAD1 on cell adhesion may be related to its function in ovarian cancer.
  • Failure of paclitaxel to affect ovarian cancer cell adhesion in presence of OCIAD1 raises the possibility of OCIAD1's role in tumor metastasis.
  • Ongoing studies using a mouse orthotopic LPA-dependent ovarian cancer metastasis model are focused on strategies to inhibit the potential role of OCIAD1 in tumor metastasis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Neoplasm Proteins / metabolism. Ovarian Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328549.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Collagen Type I; 0 / Laminin; 0 / Lysophospholipids; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / ovarian cancer immuno-reactive antigen domain containing 1, human; 22002-87-5 / lysophosphatidic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Ceelen WP, Påhlman L, Mahteme H: Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res; 2007;134:195-214
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The superiority of combined ip and intravenous chemotherapy over intravenous chemotherapy alone has been established in randomized trials in stage IIIc ovarian cancer patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Infusions, Parenteral / methods. Neoplasms / metabolism. Peritoneum / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633055.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  •  go-up   go-down


21. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA: Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg; 2009 Apr;208(4):614-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience.
  • All stage IIIC ovarian cancer patients at our institution were evaluated for tumor dissemination, age, performance status, surgical complexity, residual disease (RD), morbidity, and mortality.
  • [MeSH-major] Gynecologic Surgical Procedures / methods. Outcome Assessment (Health Care). Ovarian Neoplasms / surgery. Quality Assurance, Health Care / organization & administration

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476798.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zhao XD, Zhang Y, He SR, Yang L: [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. Ai Zheng; 2005 Dec;24(12):1542-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
  • BACKGROUND & OBJECTIVE: The first-line adjuvant chemotherapy regimens of ovarian cancer mainly include TC (paclitaxel combined with carboplatin) and PC (cisplatin combined with cyclophosphamide) protocols.
  • This study was to investigate the correlation of P53 expression to treatment outcome of ovarian cancer patients received the above 2 protocols, and explore the predictive value of P53 expression in selecting chemotherapy regimen.
  • METHODS: Records of 53 patients with advanced epithelial ovarian cancer (stage IIIc), treated with TC or PC regimen, were analyzed retrospectively.
  • CONCLUSIONS: P53 detection may play a role in selecting first-line chemotherapy for advanced epithelial ovarian cancer patients: TC regimen is preference for P53-positive patients, PC regimen may be a choice for P53-negative patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351810.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Bristow RE, Palis BE, Chi DS, Cliby WA: The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol; 2010 Sep;118(3):262-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
  • OBJECTIVE: To examine the effect of hospital procedure volume and other prognostic variables on overall survival outcome and likelihood of receiving standard recommended care among patients with advanced-stage epithelial ovarian cancer.
  • METHODS: The National Cancer Data Base (NCDB) was searched for patients undergoing primary treatment for FIGO Stage IIIC/IV epithelial ovarian cancer from 1996 to 2005.
  • Cox proportional hazards modeling was used to determine the impact on overall survival of hospital surgical volume adjusted for treatment, FIGO/AJCC stage, ethnicity, age, payer status, household income, and tumor grade.
  • CONCLUSIONS: Hospital ovarian cancer surgical volume >or=21 cases/year is associated with a higher likelihood of patients with Stage IIIC/IV epithelial ovarian cancer receiving standard treatment (surgery followed by adjuvant chemotherapy).
  • [MeSH-major] Gynecologic Surgical Procedures / statistics & numerical data. Hospitals / statistics & numerical data. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery


24. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA: Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer; 2006 Mar 27;94(6):814-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
  • To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted.
  • Persisting abnormalities indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found.
  • The effectiveness of screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing this to the identified number of ovarian cancers.
  • The number of ovarian cancer patients found at surveillance was in accordance with the predicted number of ovarian cancers.
  • A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb was found.
  • In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient.
  • For prevention of advanced stage ovarian cancer, prophylactic BSO from age 35-40 years is a more efficient alternative.
  • [MeSH-major] Genetic Predisposition to Disease. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 1999 Nov;78(10):906-11 [10577622.001]
  • [Cites] Gynecol Oncol. 2000 Jan;76(1):45-50 [10620440.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6890-8 [16129845.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):110-7 [10861460.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2728-32 [10894872.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jan-Feb;12(1):86-91 [11860541.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1260-8 [11870168.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1609-15 [12023992.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1616-22 [12023993.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1117-30 [12677558.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Apr;21(4):378-85 [12704748.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4034-41 [14581427.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1492-7 [15083174.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):357-64 [15382059.001]
  • [Cites] Gynecol Oncol. 1991 Nov;43(2):92-7 [1743564.001]
  • [Cites] Am J Hum Genet. 1995 Dec;57(6):1457-62 [8533776.001]
  • [Cites] Science. 1996 Apr 5;272(5258):123-6 [8600523.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1922-6 [10023316.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):276-92 [15637391.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(4):549-54 [15737559.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):476-82 [15863147.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5588-96 [16110018.001]
  • [CommentIn] Br J Cancer. 2006 Oct 23;95(8):1124; author reply 1126-7 [17047658.001]
  • [CommentIn] Br J Cancer. 2006 Oct 23;95(8):1125; author reply 1126-7 [17047659.001]
  • (PMID = 16495917.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC2361371
  •  go-up   go-down


25. Nwanodi O, Choi C, Khulpateea N: Cervicovaginal cytology and diagnosis of ovarian or peritoneal cancer: case report and literature review. Arch Gynecol Obstet; 2008 Feb;277(2):171-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervicovaginal cytology and diagnosis of ovarian or peritoneal cancer: case report and literature review.
  • BACKGROUND: The characteristics of women presenting with asymptomatic ovarian or peritoneal cancer diagnosed following evaluation for abnormal cervicovaginal cytology are currently undefined.
  • CASE: We present a case of a 51-year-old woman with asymptomatic stage IIIC ovarian cancer whose diagnosis was triggered by evaluation for adenocarcinoma and atypical glandular cells of undetermined significance (AGUS) on cervical cytology.
  • We also present a case of a 53-year-old woman with AGUS cervical cytology on two occasions, found to have stage III peritoneal cancer at exploratory laparotomy.
  • CONCLUSION: We conducted a systematic search for articles to enable a review of asymptomatic cases of ovarian and peritoneal cancer, which presented via abnormal cervicovaginal cytology.
  • The mean age at presentation with peritoneal cancer was 47.8 years old, which is similar to that of ovarian cancer of 50.5 years.
  • Staging was provided in 13 cases, 11 of which (85%) were at least stage IIIA or greater.
  • In terms of age greater than 50 years old, cervicovaginal cytology interpreted as AGUS, having a negative initial work-up, and advanced disease stage at presentation, the two cases presented are consistent with the literature.
  • Abnormal cervicovaginal cytology as a presenting diagnostic criterion of cancer of the ovary or peritoneum is often representative of advanced disease.
  • [MeSH-major] Cervix Uteri / pathology. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / therapy. Carcinoma, Papillary / diagnosis. Female. Humans. Middle Aged. Neoplasm Staging. Precancerous Conditions / pathology


26. Rochet N, Sterzing F, Jensen A, Dinkel J, Herfarth K, Schubert K, Eichbaum M, Schneeweiss A, Sohn C, Debus J, Harms W: Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol; 2008 Mar;184(3):145-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe a new intensity-modulated radiotherapy (IMRT) technique using helical tomotherapy for whole abdominal irradiation (WAI) in patients with advanced ovarian cancer.
  • MATERIAL AND METHODS: A patient with radically operated ovarian cancer FIGO stage IIIc was treated in a prospective clinical trial with WAI to a total dose of 30 Gy in 1.5-Gy fractions as an additional therapy after adjuvant platinum-based chemotherapy.
  • [MeSH-major] Abdomen / radiation effects. Ovarian Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Algorithms. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / radiation effects. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Kidney / radiation effects. Liver / radiation effects. Middle Aged. Neoplasm Staging. Ovary / pathology. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Prospective Studies. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Time Factors. Tomography, Spiral Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330510.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Burgert JM: Intraosseous infusion of blood products and epinephrine in an adult patient in hemorrhagic shock. AANA J; 2009 Oct;77(5):359-63
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her medical history included recurrent stage IIIC ovarian cancer.
  • [MeSH-minor] Aged. Anesthesia Recovery Period. Catheterization, Central Venous / adverse effects. Catheterization, Peripheral / adverse effects. Equipment Failure. Female. Hematemesis / etiology. Humans. Nurse Anesthetists. Ovarian Neoplasms / complications. Patient Selection. Postoperative Care / methods. Resuscitation / instrumentation. Tibia

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911645.001).
  • [ISSN] 0094-6354
  • [Journal-full-title] AANA journal
  • [ISO-abbreviation] AANA J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; YKH834O4BH / Epinephrine
  •  go-up   go-down


28. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol; 2006 Jan;107(1):77-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
  • OBJECTIVE: Residual disease after initial surgery for ovarian cancer is the strongest prognostic factor for survival.
  • Our goal was to estimate the effect of aggressive surgical resection on ovarian cancer patient survival.
  • METHODS: A retrospective cohort study of consecutive patients with International Federation of Gynecology and Obstetrics stage IIIC ovarian cancer undergoing primary surgery was conducted between January 1, 1994, and December 31, 1998.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Neoplasm, Residual / surgery. Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery. Ovariectomy / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394043.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Takeyama S, Aoki Y, Kamimura N, Suzuki M, Tanaka K: Retrieval of intraperitoneal Penrose drain under transvaginal endoscopic guidance. Gynecol Oncol; 2006 Aug;102(2):391-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 49-year-old woman with the International Federation of Gynecology and Obstetrics (FIGO) stage IIIc ovarian cancer underwent bilateral salpingo-oophorectomy, total hysterectomy, partial omentectomy, and pelvic and para-aortic lymph nodes removal.
  • [MeSH-major] Drainage / instrumentation. Foreign Bodies / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542713.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ryu HS: Should we modify the current FIGO staging system for stage IIIC ovarian cancer? J Gynecol Oncol; 2008 Dec;19(4):207-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):226-32 [2772792.001]
  • [Cites] Gynecol Oncol. 1987 Jul;27(3):368-72 [3623232.001]
  • [Cites] Gynecol Oncol. 1983 Aug;16(1):95-100 [6884834.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1555-60 [9781949.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):467-72 [9190977.001]
  • (PMID = 19471579.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676476
  •  go-up   go-down






Advertisement